Rakovina Therapeutics Inc. (TSXV: RKV)
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Delta Air Lines (DAL -10.3%) says it will launch a program next week to test employees for active COVID-19 and antibodies.
The company is partnering with the Mayo Clinic and Quest Diagnostics (DGX -2.4%) on the program.
Delta CEO Ed Bastian says the goal is for the program to evolve into a full testing protocol for all employees.
CVS Health (NYSE:CVS) to open 10 new COVID-19 test sites at select CVS Pharmacy drive-thru locations across Kansas, on Friday, June 12.
These new sites will utilize self-swab tests and deliver on the company’s promise to establish 1,000 locations across the country and help enable a goal of processing up to 1.5M tests per month, contingent on availability of supplies and lab capacity.
Shares are down 2% premarket.
Regeneron Pharmaceuticals (NASDAQ:REGN) launches the first clinical trial evaluating REGN-COV2 (REGN10933 + REGN10987), its dual antibody cocktail, for the prevention and treatment of COVID-19.
The clinical program will involve four populations: hospitalized patients, non-hospitalized symptomatic patients, uninfected people in groups at high risk of exposure and uninfected people with close exposure to a COVID-19 patient.
The first two adaptive Phase 1/2/3 trials will involve hospitalized and non-hospitalized patients with COVID-19. Results from the Phase 1 & 2 portions will inform the endpoints and size of the Phase 3s.
The company says the two antibodies bind non-competitively to the critical receptor-binding domain of the SARS-CoV-2 spike protein.
Sorrento Therapeutics (NASDAQ:SRNE) is up 21% premarket on the heels of its announcement that an application for Emergency Use Authorization (EUA) is under FDA review for company’s COVI-TRACK in vitro diagnostic test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus.
The rapid antibody test allows for results to be available in eight minutes or less.
Analytical validation was performed by testing sample cohorts from healthy donors and positive COVID-19 patient samples, and the assay demonstrated a specificity >97% and diagnostic sensitivity of >94%.
Sorrento has secured manufacturing capacity to support the production of up to five million test kits per month.
BIOLASE (NASDAQ:BIOL) has closed its registered direct offering of 10.8M common shares and accompanying warrants to purchase the same number of common shares at $0.64.
Gross proceeds were~$6.9M.
Net proceeds will be used for working capital and other general corporate purposes.
Shares are down 3% premarket.
